Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice

Hironobu Takano _, Toru Nakamura, Takahiro Tsuchikawa, Toshihiro Kushibiki, Kouji Hontani, Kazuho Inoko, Mizuna Takahashi, Shoki Sato, Hirotake Abe, Shintaro Takeuchi, Nagato Sato, Kei Hiraoka, Hiroshi Nishihara, Toshiaki Shichinohe and Satoshi Hirano

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:41063-41076. https://doi.org/10.18632/oncotarget.5729

Metrics: PDF 1771 views | HTML 2441 views | ?

Abstract

Hironobu Takano1, Toru Nakamura1, Takahiro Tsuchikawa1, Toshihiro Kushibiki1, Kouji Hontani1, Kazuho Inoko1, Mizuna Takahashi1, Shoki Sato1, Hirotake Abe1, Shintaro Takeuchi1, Nagato Sato1, Kei Hiraoka1, Hiroshi Nishihara2, Toshiaki Shichinohe1, Satoshi Hirano1

1Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan

2Department of Translational Pathology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan

Correspondence to:

Toru Nakamura, e-mail: [email protected]

Keywords: EphA4, prognostic factor, 2,5-dimethylpyrrolyl benzoic acid, human pancreatic cancer, orthotopic models

Received: April 21, 2015 Accepted: September 20, 2015 Published: October 19, 2015

ABSTRACT

Ephrin receptor A4 (EphA4) is overexpressed in human pancreatic adenocarcinoma (PDAC) and activate cell growth. Recent studies have identified small molecules that block EphA4. In this study, we investigated the correlation between EphA4 expression and the prognosis of patients with PDAC. We also examined the cytostatic efficacy of 2,5-dimethylpyrrolyl benzoic acid (compound 1), a small molecule that blocks EphA4, in PDAC cells. Overall survival of patients with EphA4 positivity was significantly shorter than that of patients with EphA4 negativity (P = 0.029). In addition, multivariate analysis revealed that EphA4 expression was an independent prognostic factor in PDAC patients (P = 0.039). Compound 1 showed a cytostatic efficacy in PDAC cells expressing EphA4 in vitro and in vivo. Our study indicated that compound 1 suppressed both EphA4 and Akt phosphorylations, and induced apoptosis in PDAC cells expressing EphA4. In conclusion, compound 1 has a high potential as a therapeutic agent for patients with PDAC.

Creative Commons License

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5729